NSE: ABBOTINDIA | BSE: 500488

Expensive Performer

Download real time

30720.55 151.40 (0.50%)

Near 52W High of ₹31898.95

6,130 NSE+BSE Volume

NSE 28 Mar, 2025 3:43 PM (IST)

65,279

Market Cap

High in industry

0.4

Beta 1Year

Very Low volatility

Abbott India Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ABBOTINDIA, BSE:500488 Abbott India Ltd.

Search Inside the pdf :

Abbott India Ltd.

06 Feb 2025

30720.55

0.50%

Stellar quarter; growth pace accelerating

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) impressive revenue growth of 12.3% YoY in Q3FY25 was ahead of our expectation. As per IQVIA, this may be driven by key brands of Novo Nordisk like Rybelsus and Ryzodeg and owned brands like Duphalac, Udiliv and Thyronorm.

Abbott India Ltd. is trading above all available SMAs

Abbott India Ltd.

06 Feb 2025

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We maintain a BUY rating on the stock

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Ltd.

08 Nov 2024

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Axis Direct

we maintain a BUY rating on the stock. We have set a target price of Rs 31,420/share, which implies an upside potential of 12% from the CMP.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

26 Oct 2024

30720.55

0.50%

Pick of the Week:28 October 2024

Buy: Abbott India Ltd.

Target

Axis Direct

We recommend a BUY with a target price of Rs 31,420/share (46.5x P/E for FY26E), implying an upside of 10% from the CMP.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

08 Aug 2024

30720.55

0.50%

Healthy earnings: growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

Earnings were in line with our estimates, where sales grew by 5% y-o-y to Rs 1,557 crore (1.6% below our estimates), EBITDA grew by 10% y-o-y to Rs 3,910 crore.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

08 Aug 2024

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We have BUY on the Stock

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Ltd.

12 May 2024

30720.55

0.50%

Sailing through turbulence

Buy: Abbott India Ltd.

Target

ICICI Securities Limited

Abbott India’s (Abbott) Q4FY24 revenue growth of 7% was slightly below expectation of 9%; however, its 9.4% growth in FY24 was still ahead of industry growth of ~8%. Sequential drop of 197/407bps in gross/EBITDA margin was on account of higher third-party sourcing and higher overhead cost.

Abbott India Ltd. has an average target of 31900.00 from 3 brokers.

Abbott India Ltd.

10 May 2024

30720.55

0.50%

Result Update:Abbott India

Buy: Abbott India Ltd.

Target

Axis Direct

We have BUY on the stock.

Number of FII/FPI investors decreased from 85 to 78 in Dec 2024 qtr

Abbott India Ltd.

09 May 2024

30720.55

0.50%

Healthy earnings; growth momentum to continue

Buy: Abbott India Ltd.

Target

Sharekhan

? Abbott reported healthy earnings an annual basis but earnings lagged our estimates where sales grew by 7%
y-o-y to Rs 1438 crore (1.3% below our estimates), EBITDA grew by 17.7% y-o-y to Rs 329 crore (13% below our estimates) and PAT grew by 29% y-o-y to Rs 287 crore (4% below our estimates).